U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H12Cl2N2O5
Molecular Weight 323.1297
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORAMPHENICOL

SMILES

c1cc(ccc1[C@]([H])([C@@]([H])(CO)N=C(C(Cl)Cl)O)O)N(=O)=O

InChI

InChIKey=WIIZWVCIJKGZOK-RKDXNWHRSA-N
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H12Cl2N2O5
Molecular Weight 323.1297
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Streptomyces venezuelae in 1947. The drug was subsequently chemically synthesized. It has both a bacteriostatic and bactericidal effect; in the usual therapeutic concentrations it is bacteriostatic. Chloramphenicol is used for the treatment of serious gram-negative, gram-positive, and anaerobic infections. It is especially useful in the treatment of meningitis, typhoid fever, and cystic fibrosis. It should be reserved for infections for which other drugs are ineffective or contraindicated. Chloramphenicol, a small inhibitor of bacterial protein synthesis, is active against a variety of bacteria and readily enters the CSF. It has been used extensively in the last decades for the treatment of bacterial meningitis. In industrialized countries, chloramphenicol is restricted mostly to topical uses because of the risk of induction of aplastic anemia. However, it remains a valuable reserve antibiotic for patients with allergy to β-lactam antibiotics or with CNS infections caused by multiresistant pathogens.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CHLOROPTIC

Approved Use

Indications and Usage In accord with the concepts in the Warning Box and this section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above. 1. Acute infections caused by Salmonella typhi* It is not recommended for the routine treatment of the typhoid carrier state. 2. Serious infections caused by susceptible strains in accordance with the concepts expressed above: a) Salmonella species b) H. influenzae, specially meningeal infections c) Rickettsia d) Lymphogranuloma-psittacosis group e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents. 3. Cystic fibrosis regimens *In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse.

Launch Date

-56332800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.9 μg/mL
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
59.1 μg × h/mL
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.1 h
25 mg/kg 4 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
2.2 h
25 mg/kg 4 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL SUCCINATE serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 4 times / day multiple, ophthalmic
Recommended
Dose: 0.5 %, 4 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 4 times / day
Sources:
unhealthy, 0.5 - 12 years
Health Status: unhealthy
Age Group: 0.5 - 12 years
Sex: unknown
Sources:
Other AEs: Swollen eyelid...
Other AEs:
Swollen eyelid (1 patient)
Sources:
0.25 g 1 times / 3 months multiple, intramuscular
Recommended
Dose: 0.25 g, 1 times / 3 months
Route: intramuscular
Route: multiple
Dose: 0.25 g, 1 times / 3 months
Sources:
unhealthy, 11 years
Health Status: unhealthy
Age Group: 11 years
Sex: F
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
70 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 70 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 70 mg/kg, 1 times / day
Sources:
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: F
Sources:
Disc. AE: Hyperlactatemia...
AEs leading to
discontinuation/dose reduction:
Hyperlactatemia (1 patient)
Sources:
3 g 1 times / day multiple, intravenous
Recommended
Dose: 3 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 23 years
Health Status: unhealthy
Age Group: 23 years
Sex: M
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
2.5 g 1 times / day multiple, intravenous
Recommended
Dose: 2.5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 g, 1 times / day
Sources:
unhealthy, 27 years
Health Status: unhealthy
Age Group: 27 years
Sex: F
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
1 g 1 times / day multiple, parenteral
Recommended
Dose: 1 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 39 years
Health Status: unhealthy
Age Group: 39 years
Sex: M
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
750 mg 4 times / day steady, intravenous
Recommended
Dose: 750 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 750 mg, 4 times / day
Sources:
unhealthy, 54 years
Health Status: unhealthy
Age Group: 54 years
Sex: M
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
4 g 1 times / day multiple, intravenous
Recommended
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
1 g 1 times / day multiple, intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
2 g 1 times / day multiple, parenteral
Recommended
Dose: 2 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 71 years
Health Status: unhealthy
Age Group: 71 years
Sex: F
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
AEs

AEs

AESignificanceDosePopulation
Swollen eyelid 1 patient
0.5 % 4 times / day multiple, ophthalmic
Recommended
Dose: 0.5 %, 4 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 4 times / day
Sources:
unhealthy, 0.5 - 12 years
Health Status: unhealthy
Age Group: 0.5 - 12 years
Sex: unknown
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
0.25 g 1 times / 3 months multiple, intramuscular
Recommended
Dose: 0.25 g, 1 times / 3 months
Route: intramuscular
Route: multiple
Dose: 0.25 g, 1 times / 3 months
Sources:
unhealthy, 11 years
Health Status: unhealthy
Age Group: 11 years
Sex: F
Sources:
Hyperlactatemia 1 patient
Disc. AE
70 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 70 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 70 mg/kg, 1 times / day
Sources:
unhealthy, 15 years
Health Status: unhealthy
Age Group: 15 years
Sex: F
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
3 g 1 times / day multiple, intravenous
Recommended
Dose: 3 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 23 years
Health Status: unhealthy
Age Group: 23 years
Sex: M
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
2.5 g 1 times / day multiple, intravenous
Recommended
Dose: 2.5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 g, 1 times / day
Sources:
unhealthy, 27 years
Health Status: unhealthy
Age Group: 27 years
Sex: F
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
1 g 1 times / day multiple, parenteral
Recommended
Dose: 1 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 39 years
Health Status: unhealthy
Age Group: 39 years
Sex: M
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
750 mg 4 times / day steady, intravenous
Recommended
Dose: 750 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 750 mg, 4 times / day
Sources:
unhealthy, 54 years
Health Status: unhealthy
Age Group: 54 years
Sex: M
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
4 g 1 times / day multiple, intravenous
Recommended
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy, 61 years
Health Status: unhealthy
Age Group: 61 years
Sex: M
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
1 g 1 times / day multiple, intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
2 g 1 times / day multiple, parenteral
Recommended
Dose: 2 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 71 years
Health Status: unhealthy
Age Group: 71 years
Sex: F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Numerical methods for handling uncertainty in microarray data: an example analyzing perturbed mitochondrial function in yeast.
2001
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA.
2001
Amplification of the Escherichia coli lacZ gene in Bacillus subtilis and its expression on a by-product growth medium.
2001
Comparative review of topical ophthalmic antibacterial preparations.
2001
The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs.
2001
Disposition kinetics of florfenicol in goats by using two analytical methods.
2001 Apr
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.
2001 Apr
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia.
2001 Apr
Randomised controlled trial of ketorolac in the management of corneal abrasions.
2001 Apr
Intraabdominal vancomycin-resistant enterococcus infections: the new threat.
2001 Apr
Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells.
2001 Apr
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
2001 Apr
The epithelial flap for photorefractive keratectomy.
2001 Apr
The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal.
2001 Apr
Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance.
2001 Apr
An outbreak of Salmonella enteritidis infection in pygmy hogs (Sus salvanius).
2001 Apr
Plasmid transfer and susceptibility to antibiotics in the halophilic phototrophs Rhodovibrio salinarum and Rhodothalassium salexigens.
2001 Apr 1
Streptococcus pneumoniae nasopharyngeal carriage prevalence, serotype distribution, and resistance patterns among children on Lombok Island, Indonesia.
2001 Apr 1
Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains.
2001 Apr 27
Liposome-mediated DNA uptake and transient expression in Thermotoga.
2001 Feb
Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia.
2001 Feb
Determination of assay and impurities of gamma irradiated chloramphenicol in eye ointment.
2001 Feb
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
2001 Feb
Vibrio parahaemolyticus associated with cholera-like diarrhea among patients in North Jakarta, Indonesia.
2001 Feb
Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity.
2001 Feb 14
A limited loss of DNA compaction accompanying the release of cytoplasm from cells of Escherichia coli.
2001 Jan
Inactivation of chloramphenicol by Staphylococcus aureus biotype C from humans & animals.
2001 Jan
Shigella and Salmonella strains isolated from children under 5 years in Gaborone, Botswana, and their antibiotic susceptibility patterns.
2001 Jan
Mesophyll-specific, light and metabolic regulation of the C4 PPCZm1 promoter in transgenic maize.
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
Bacteraemia and mortality among adult medical admissions in Malawi--predominance of non-typhi salmonellae and Streptococcus pneumoniae.
2001 Jan
[Pneumococcal antibiotic resistance in 1999. Results from 19 registries for 1999].
2001 Jan
Lack of evidence for chloramphenicol resistance in Neisseria meningitidis, Africa.
2001 Jan-Feb
[Methods of determining chloramphenicol in the workplace air].
2001 Jan-Feb
A novel heat shock protein plays an important role in thermal stress management in cyanobacteria.
2001 Jul 6
Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain.
2001 Jun
Occurrence of the vanA and vanC2/C3 genes in Enterococcus species isolated from poultry sources in Malaysia.
2001 Mar
Antimicrobial susceptibility of Listeria monocytogenes isolated from meningoencephalitis in sheep.
2001 Mar
Antimicrobial resistance of Enterococci in Lebanon.
2001 Mar
Factors involved in the (near) anoxic survival time of Cerastoderma edule: associated bacteria vs. endogenous fuel.
2001 Mar
Improved agar diffusion method for detecting residual antimicrobial agents.
2001 Mar
In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes.
2001 Mar-Apr
In vitro susceptibility of Vibrio spp. isolated from the environment.
2001 May
In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico.
2001 May
Carriage of antibiotic-resistant bacteria by healthy children.
2001 May
Comparative study of the influence of melatonin and vitamin E on the surface characteristics of Escherichia coli.
2001 May
Chromate tolerant bacteria isolated from tannery effluent.
2001 May
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods.
2001 Spring
Patents

Sample Use Guides

Chloramphenicol 0.5% Eye Drops
Route of Administration: Topical
The highest activity of chloramphenicol was documented for isolates of Stenotrophomonas maltophilia (76,5 % susceptible, MIC50 = 4 mg/L, MIC90 = 16 mg/L) and of Staphylococcus aureus (76,2 % susceptible, MIC50 = 8 mg/L, MIC90 = 16 mg/L).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:05:04 UTC 2021
Edited
by admin
on Fri Jun 25 21:05:04 UTC 2021
Record UNII
66974FR9Q1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORAMPHENICOL
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CHLORAMPHENICOL [MI]
Common Name English
CHLOROPTIC-P S.O.P. COMPONENT CHLORAMPHENICOL
Common Name English
NSC-3069
Code English
OPHTHOCHLOR
Brand Name English
CHLOROMYCETIN
Brand Name English
CHLORAMPHENICOL [MART.]
Common Name English
CHLORAMPHENICOL [HSDB]
Common Name English
MYCHEL
Brand Name English
CHLORAMPHENICOL COMPONENT OF CHLOROMYXIN
Common Name English
CHLOROPTIC
Brand Name English
CHLORAMPHENICOL [USP-RS]
Common Name English
CHLORAMPHENICOL [WHO-DD]
Common Name English
CHLORAMPHENICOLUM
HPUS   WHO-IP LATIN  
Common Name English
D-THREO-(-)-2,2-DICHLORO-N-(.BETA.-HYDROXY-.ALPHA.-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE
Common Name English
CHLORAMPHENICOL [GREEN BOOK]
Common Name English
CHLORAMPHENICOL [WHO-IP]
Common Name English
2,2-DICHLORO-N-((1R,2R)-2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)ACETAMIDE
Systematic Name English
OPHTHOCORT COMPONENT CHLORAMPHENICOL
Common Name English
CHLORAMPHENICOL [USP]
Common Name English
CHLORAMPHENICOL [INN]
Common Name English
CHLORAMPHENICOL [ORANGE BOOK]
Common Name English
CHLORAMPHENICOL COMPONENT OF CHLOROMYCETIN HYDROCORTISONE
Common Name English
CHLORAMPHENICOL COMPONENT OF CHLOROPTIC-P S.O.P.
Common Name English
OPTOMYCIN
Brand Name English
NOVOMYCETIN
Common Name English
CHLORAMPHENICOL [VANDF]
Common Name English
CHLOROMYCETIN HYDROCORTISONE COMPONENT CHLORAMPHENICOL
Common Name English
ELASE-CHLOROMYCETIN COMPONENT CHLORAMPHENICOL
Common Name English
CHLORAMPHENICOL [JAN]
Common Name English
CHLORAMPHENICOL COMPONENT OF ELASE-CHLOROMYCETIN
Common Name English
CHLORAMPHENICOLUM [HPUS]
Common Name English
SYNTHOMYCETIN
Common Name English
CHLORAMPHENICOL [IARC]
Common Name English
CHLORAMPHENICOLUM [WHO-IP LATIN]
Common Name English
CHLORAMPHENICOL [EP MONOGRAPH]
Common Name English
AMPHICOL
Brand Name English
CHLORAMPHENICOL COMPONENT OF OPHTHOCORT
Common Name English
CHLOROMYXIN COMPONENT CHLORAMPHENICOL
Common Name English
ECONOCHLOR
Brand Name English
ACETAMIDE, 2,2-DICHLORO-N-(2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)-, (R-(R*,R*))-
Common Name English
CHLOROFAIR
Brand Name English
Classification Tree Code System Code
WHO-VATC QD10AF03
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
NCI_THESAURUS C258
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC G01AA05
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC S03AA08
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QD06AX02
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QG01AA55
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QJ01BA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 524.390
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 530.41
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QS03AA08
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC D10AF03
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC D06AX02
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 520.390
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
IARC Chloramphenicol
WHO-VATC QJ51BA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QJ51RB01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QS02AA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
NDF-RT N0000175479
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
NDF-RT N0000175479
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 522.390
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC J01BA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
NDF-RT N0000175480
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QG01AA05
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC S01AA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 520.390A
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
LIVERTOX 190
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-ATC S02AA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
WHO-VATC QS01AA01
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
CFR 21 CFR 520.390B
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
Code System Code Type Description
MESH
D002701
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
CAS
56-75-7
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
INN
977
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
NCI_THESAURUS
C363
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
EPA CompTox
56-75-7
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
HSDB
3027
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-287-4
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
PUBCHEM
5959
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
DRUG BANK
DB00446
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
MERCK INDEX
M3347
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL130
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
LACTMED
Chloramphenicol
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
USP_CATALOG
1107004
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY USP-RS
FDA UNII
66974FR9Q1
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
DRUG CENTRAL
589
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
EVMPD
SUB06173MIG
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
WIKIPEDIA
CHLORAMPHENICOL
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY
RXCUI
2348
Created by admin on Fri Jun 25 21:05:04 UTC 2021 , Edited by admin on Fri Jun 25 21:05:04 UTC 2021
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME->WEAK INHIBITOR
COMPETITIVE INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
METABOLIC ENZYME -> NON-INHIBITOR
METABOLIC ENZYME -> NON-INHIBITOR
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INHIBITOR
MIXED INHIBITION
MAJOR
Ki
METABOLIC ENZYME -> NON-INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Colourless to greyish white or yellowish white, needle-like crystals or elongated plates or a crystalline powder; odourless.
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC